Picture of Revive Therapeutics logo

RVV — Revive Therapeutics Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+13.18%
3m+222.04%
6m+46.57%
1yr-20.06%
Volume Change (%)
10d/3m-21.09%
Price vs... (%)
52w High-28.57%
50d MA+20.66%
200d MA+23.3%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-154.89%
Return on Equity-102.68%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Revive Therapeutics EPS forecast chart

Profile Summary

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for infectious diseases and rare disorders. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Directors

Last Annual
June 30th, 2021
Last Interim
March 31st, 2022
Incorporated
March 27th, 2012
Public Since
July 12th, 2013
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconCanadian Securities Exchange
Shares in Issue
320,677,951

RVV Share Price Performance

Upcoming Events for RVV

Revive Therapeutics Ltd Extraordinary Shareholders Meeting

Revive Therapeutics Ltd Annual Shareholders Meeting

Q4 2022 Revive Therapeutics Ltd Earnings Release

Q1 2023 Revive Therapeutics Ltd Earnings Release

Similar to RVV

Picture of Albert Labs International logo

Albert Labs International

ca flag iconCanadian Securities Exchange

Picture of Algernon Pharmaceuticals logo

Algernon Pharmaceuticals

ca flag iconCanadian Securities Exchange

Picture of Asep Medical Holdings logo

Asep Medical Holdings

ca flag iconCanadian Securities Exchange

Picture of Avisa Diagnostics logo

Avisa Diagnostics

ca flag iconCanadian Securities Exchange

Picture of BetterLife Pharma logo

BetterLife Pharma

ca flag iconCanadian Securities Exchange

FAQ

Or unlock with your email

Or unlock with your email